Replies to post #344892 on Amarin Corp Plc (AMRN)

[Number sleven]

Raf, Thanks for posting the numbers. What do we make of this? Our prescriptions are down but gv was down more.
Sleven,

[dukesking]

Raf, Thanks for continuing to supply the script numbers. GL is up again and continues taking CVD shares. It’s a shame that doctors are still prescribing GL for CVD. Between the profit motivated generic schemes and uniformed doctors, it seems this will continue indefinitely. I just hope AMRN can grow scripts along with the entire prescription O3 market.

[rafunrafun]

Scripts for week ending June 25, 2021.

Overall drug TRx are -2.4% w/w.

Vascepa
TRx 83,250; -1.2% (-992) w/w; -2.2% y/y
NRx 36,684; -0.8% (-313) w/w; -1.4% y/y
Ref 46,387; -1.4% (-678) w/w; +0.9% y/y

Lovaza (Generic & Brand)
TRx 62,643; -4.1% (-2,672) w/w; +2.3% y/y
NRx 30,763; -2.9% (-933) w/w; +3.9% y/y
Ref 31,881; -5.2% (-1,739) w/w; +0.8% y/y

Generic Vascepa
TRx 13,996; +2.2% (+295)w/w; As % of total V: 14.4%
NRx 7,802; +4.4% (+329) w/w; As % of total V: 17.5%
Ref 6,194; -0.5% (-34) w/w; As % of total V: 11.8%

Of the 13,196 gV TRx, 62 were from Dr. Reddy. (53 NRx / 9 Refill)